Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical

Transcription

1 Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical February 26, 2008 FORWARD-LOOKING STATEMENTS Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management s current assumptions and beliefs based on currently available information. Such forwardlooking statements are subject to a number of risks, uncertainties and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

2 Middle and Long Term Management Strategies Future Business Portfolio that accelerates Fujifilm s Growth Healthcare Medical Systems Life Sciences The FUJIFILM Group's Broad Range of Technologies and Know-how Chemical materials library Imaging & Communication Imaging Documents Graphic Arts Image processing technologies Highly advanced manufacturing technologies Highly Functional materials/devices Flat Panel Display Materials Optical Devices Electronic Materials Inkjet Materials

3 Expanding Business Domain Healthcare Medical systems Life sciences Prevention Internal care products X-ray imaging (FCR / film) Diagnosis Endoscopes Treatment Radiopharmaceuticals FUJIFILM RI Pharma (October 2006-) Business expansion Business expansion Functional cosmetics Blood analysis systems Radio diagnostic medicine Medical Pharmaceuticals pharmaceuticals and intermediates FUJIFILM FINECHEMICALS (January 2006-)

4 Significance of the Strategic Partnership Development of epoch-making drugs through teamwork among companies in differing industries FUJIFILM Imaging technology applicable to drug discovery Nanotechnologies and unique materials technologies applicable to regeneration medicine and drug delivery systems Global network and trusted brand Toyama Chemical A leading, world-class drug discovery company Pursuing the drug discovery mechanism Innovative, superior R&D capabilities Strong pipeline based on a new action mechanism Pharmaceuticals for treating influenza, Alzheimer s disease, and other diseases Teamwork Among These Three Companies Will Create New Value Giving consideration to collaboration in self-medication applications Teamwork in marketing by working through Taisho Toyama Pharmaceutical Taisho Pharmaceutical Self-medication and pharmaceutical business capabilities that can fully cover health maintenance/ improvement, disease prevention, and medical treatment,

5 Toyama Chemical as a Strategic Partner Fujifilm Technological synergies An R&D-oriented innovative drug developer / manufacturer Aggressive stance in incorporating cross-industrial technologies Toyama Chemical High growth potential Corporate culture that generates synergies with Fujifilm Pipeline of competitive drugs High rate of innovative drug introduction to the market Emphasis on creativity among research personnel Pursuing the mechanism of drug discovery 4

6 Future vision for the Medical Systems/Life Sciences Business Treatment Diagnosis Unique innovative drugs Toyama Chemical s technology (Pharmaceutical developer) Prevention Collaboration in the field of self-medication Taisho Pharmaceutical s development/ marketing capacity Comprehensive healthcare company that encompasses the fields of prevention, diagnosis and treatment

7 (Appendix) Scheme of the Capital Alliance Toyama Chemical allocated new shares through a third party allocation (at the end of February 2008) Companies underwriting the allocation and amounts: Expenses for R&D and capital expenditure Fujifilm: 19.8 billion Taisho Pharmaceutical: 10.2 billion TOB conducted by Fujifilm (Feb. 19 to Mar.18, 2008) TOB price: 880/share TOB minimum number of shares: 73,190,000 Toyama Chemical became a consolidated subsidiary of Fujifilm as of March 26. Fujifilm will transfer part of the shares to Taisho Pharmaceutical (Scheduled in July 2008) Using a method by which Toyama Chemical will issue a class of shares to which a provision for acquisition of common stock will be attached (such shares, "Fully Acquirable Class Shares ) Amount of cash invested in the Alliance: 130 billion (Planned) Fujifilm Fujifilm 66.0% Accept TOB General shareholders Toyama Chemical Transferring shares Toyama Chemical Taisho Pharmaceutical Taisho Pharmaceutical 34.0% Fujifilm will hold 66.0% of Toyama Chemical s shares. 6

8 We will use leading-edge, proprietary technologies to provide top-quality products and services that contribute to the advancement of culture, science, technology and industry, as well as improved health and environmental protection in society. Our overarching aim is to help enhance the quality of life of people worldwide.